The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis–associated liver tumors in a novel murine model

The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis–associated liver tumors in a novel murine model

Background: Diabetes and obesity contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). However, how diabetes and obesity accelerate liver tumorigenesis remains to be fully understood. Moreover, to verify the therapeutic potential of anti-diabetic d...

Full description

Bibliographic Details
Main Authors: Naoki Yoshioka, Miyako Tanaka, Kozue Ochi, Akiko Watanabe, Kenji Ono, Makoto Sawada, Tomoo Ogi, Michiko Itoh, Ayaka Ito, Yukihiro Shiraki, Atsushi Enomoto, Masatoshi Ishigami, Mitsuhiro Fujishiro, Yoshihiro Ogawa, Takayoshi Suganami
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Diabetes
Nonalcoholic steatohepatitis
Hepatocellular carcinoma
Animal model
Sodium glucose cotransporter 2 inhibitor
Cellular senescence
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221005205

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221005205

Similar Items